Author(s)

O. I. Ajetunmobi^1*, U. Drebber², R. Buettner², O. D. Dzuachii¹, R. A. Vhritherire³, O. A. Oguntunde⁴, O. S. Raphael⁵, O. Odujoko⁶

¹Department of Histopathology, Federal Medical Centre Makurdi, Benue State, Nigeria.
²Institute of Pathology, University Hospital Cologne, Cologne, Germany.
³Department of Histopathology, Benue State University Teaching Hospital, Makurdi, Benue State, Nigeria.
⁴Department of Histopathology, College of Medicine, University of Lagos, Lagos, Nigeria.
⁵Department of Histopathology, University of Abuja Teaching Hospital, Abuja, Nigeria.
⁶Department of Morbid Anatomy and Forensic Medicine, Obafemi Awolowo University, Osun State, Nigeria.

Introduction: Members of the Human Epidermal Receptor [HER] family of receptor tyrosine kinases, such as HER2 and EGFR proteins are overexpressed in several epithelial malignancies and serve as effective therapeutic targets in cancer management. However, their role in prostate cancer development has been sparingly explored and with contrasting findings. Notably their relationship with prostate cancers cases seen in Sub-Saharan Africa is yet to be explored. Design: A retrospective study involving histologically diagnosed cases of adenocarcinomas of the prostate. Cases were classed according to the WHO/ISUP Gleason Prognostic groups [G1 - G5]. Immunohistochemical analysis was performed using monoclonal antibodies for HER2 and EGFR, while in situ hybridization employed DNA probes for the corresponding genes. Scores of +2 and +3 were regarded as positive for both antibodies, while a target gene: centromere ratio of >2 was set as the threshold for amplification. Results: A total of 44 cases were included in the study. The acinar type was the commonest morphologically, with Gleason group 5 [Gleason scores 8 - 10] accounting for close to half of the cases [47.7%]. The HER2 antibody stained negatively in the majority of cases [93.2%], being positive in only 3 [6.8%] of cases seen. High level expression of EGFR [+2/+3] was observed in 25% of cases, low level expression was identified in 6 [13.6%] cases. All HER2 positive malignancies displayed overexpression of EGFR. In situ-hybridization revealed the absence of high level amplification for both HER2 and EGFR, while polysomy was not detected in any of the cases. Conclusion: The overexpression of EGFR in prostate cancers has been demonstrated in a native African population, affirming its suitability for targeted therapy. Overexpression of HER2 in prostate cancer is inconstant, and amplification of the HER2 gene is less frequent than as compared to malignancies of the Breast and Ovary. There’s a need for a standardized protocol for assessing HER2 in prostate cancer.

Prostate, Adenocarcinoma, Gleason, HER2, EGFR2, Amplification, FISH

Ajetunmobi, O. , Drebber, U. , Buettner, R. , Dzuachii, O. , Vhritherire, R. , Oguntunde, O. , Raphael, O. and Odujoko, O. (2019) Expression of HER Receptor Proteins in Prostate Adenocarcinoma: A Perspective from North Central Nigeria. Open Journal of Pathology, 9, 58-70. doi: 10.4236/ojpathology.2019.93007.